Update on the theory and management of orthostatic intolerance and related syndromes in adolescents and children

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 11, 2012, Pages 1387-1399

  Stewart, Julian M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

autonomic; hyperpnea; orthostatic hypotension; orthostatic tachycardia; postural tachycardia; syncope

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUDROCORTISONE; MIDODRINE; PAROXETINE; PLACEBO; PYRIDOSTIGMINE; RECOMBINANT ERYTHROPOIETIN; SEROTONIN UPTAKE INHIBITOR; THREO 3,4 DIHYDROXYPHENYLSERINE; YOHIMBINE;

ADOLESCENT; ARTERIAL PRESSURE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD PRESSURE; BLOOD VOLUME; BRAIN BLOOD FLOW; CHILD; CLINICAL FEATURE; COMPRESSION GARMENT; DIET; DIET THERAPY; EXERCISE; FAINTNESS; HEART HEMODYNAMICS; HEART RATE; HUMAN; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC INTOLERANCE; ORTHOSTATIC STRESS; PACEMAKER; PARKINSON DISEASE; PHYSICAL ACTIVITY; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; QUALITY OF LIFE; REVIEW; STANDING; SYMPATHETIC TONE; TRANSCRANIAL DOPPLER; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

ADOLESCENT; ADOLESCENT DEVELOPMENT; CHILD; CHILD DEVELOPMENT; DRINKING; HUMANS; ORTHOSTATIC INTOLERANCE; QUALITY OF LIFE; SYNCOPE;

EID: 84871297663     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.139     Document Type: Review

References (125)

1. Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am. J. Med. Sci. 317(2), 75-77 (1999).
2. LeLorier P, Klein GJ, Krahn A, Yee R, Skanes A, Shoemaker JK. Combined head-up tilt and lower body negative pressure as an experimental model of orthostatic syncope. J. Cardiovasc. Electrophysiol. 14(9), 920-924 (2003).
3. Low PA, Opfer-Gehrking TL, McPhee BR et al. Prospective evaluation of clinical characteristics of orthostatic hypotension. Mayo Clin. Proc. 70(7), 617-622 (1995).
4. Ocon AJ, Kulesa J, Clarke D, Taneja I, Medow MS, Stewart JM. Increased phase synchronization and decreased cerebral autoregulation during fainting in the young. Am. J. Physiol. Heart Circ. Physiol. 297(6), H2084-H2095 (2009).
5. Ocon AJ, Medow MS, Taneja I, Clarke D, Stewart JM. Decreased upright cerebral blood flow and cerebral autoregulation in normocapnic postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 297(2), H664-H673 (2009).
6. Mukai S, Lipsitz LA. Orthostatic hypotension. Clin. Geriatr. Med. 18(2), 253-268 (2002).
7. Medow MS, Stewart JM, Sanyal S, Mumtaz A, Sica D, Frishman WH. Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. Cardiol. Rev. 16(1), 4-20 (2008).
8. Novak V, Spies JM, Novak P, McPhee BR, Rummans TA, Low PA. Hypocapnia and cerebral hypoperfusion in orthostatic intolerance. Stroke 29(9), 1876-1881 (1998).
9. Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology 43(1), 132-137 (1993).
10. Aaslid R, Lindegaard KF, Sorteberg W, Nornes H. Cerebral autoregulation dynamics in humans. Stroke 20(1), 45-52 (1989).
11. Lassen NA. Cerebral blood flow and oxygen consumption in man. Physiol. Rev. 39(2), 183-238 (1959).
12. Iwasaki KI, Zhang R, Zuckerman JH, Pawelczyk JA, Levine BD. Effect of head-down-tilt bed rest and hypovolemia on dynamic regulation of heart rate and blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279(6), R2189-R2199 (2000).
13. The European Society of Cardiology. The European Society of Cardiology guidelines for the diagnosis and management of syncope reviewed by Angel Moya, MD, FESC, Chair of the Guideline Taskforce with J. Taylor, MPhil. Eur.Heart J. 30(21), 2539-2540 (2009).
14. Rowell LB. Human Cardiovascular Control. Oxford University Press, NY, USA (1993).
15. Miller JD, Pegelow DF, Jacques AJ, Dempsey JA. Skeletal muscle pump versus respiratory muscle pump: modulation of venous return from the locomotor limb in humans. J. Physiol. (Lond.) 563(Pt 3), 925-943 (2005).
16. Wang Y, Marsgall RJ, Shepherd JT. The effect of changes in posture and graded exercise on stroke volume in man. J. Clin. Invest. 39, 1051-1061 (1960).
17. Thijs RD, Wieling W, van den Aardweg JG, van Dijk JG. Respiratory countermaneuvers in autonomic failure. Neurology 69(6), 582-585 (2007).
18. van Dijk N, de Bruin IG, Gisolf J et al. Hemodynamic effects of leg crossing and skeletal muscle tensing during free standing in patients with vasovagal syncope. J. Appl. Physiol. 98(2), 584-590 (2005).
19. Jacob G, Ertl AC, Shannon JR, Furlan R, Robertson RM, Robertson D. Effect of standing on neurohumoral responses and plasma volume in healthy subjects. J. Appl. Physiol. 84(3), 914-921 (1998).
20. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ. Res. 90(12), 1316-1324 (2002).
21. Shipley RD, Kim SJ, Muller-Delp JM. Time course of flow-induced vasodilation in skeletal muscle: contributions of dilator and constrictor mechanisms. Am. J. Physiol. Heart Circ. Physiol. 288(4), H1499-H1507 (2005).
22. Raczak G, La Rovere MT, Mortara A et al. Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation. J. Heart Lung Transplant. 18(5), 399-406 (1999).
23. Brack KE, Coote JH, Ng GA. Vagus nerve stimulation inhibits the increase in Ca2+ transient and left ventricular force caused by sympathetic nerve stimulation but has no direct effects alone - epicardial Ca2+ fluorescence studies using fura-2 AM in the isolated innervated beating rabbit heart. Exp. Physiol. 95(1), 80-92 (2010).
24. Toda N, Ayajiki K, Okamura T. Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol. Rev. 61(1), 62-97 (2009).
25. Liu JL, Murakami H, Zucker IH. Angiotensin II-nitric oxide interaction on sympathetic outflow in conscious rabbits. Circ. Res. 82(4), 496-502 (1998).
26. Macarthur H, Wilken GH, Westfall TC, Kolo LL. Neuronal and non-neuronal modulation of sympathetic neurovascular transmission. Acta Physiol. (Oxf). 203(1), 37-45 (2011).
27. Von Euler US. Identification of the sympathomimetic ergone in adrenergic nerves of cattle (sympathin N) with levo-noradrenaline. Acta Physiol. Scandinav. 1663-1674 (1948).
28. Taneja I, Moran C, Medow MS, Glover JL, Montgomery LD, Stewart JM. Differential effects of lower body negative pressure and upright tilt on splanchnic blood volume. Am. J. Physiol. Heart Circ. Physiol. 292(3), H1420-H1426 (2007).
29. Sheriff DD, Nådland IH, Toska K. Role of sympathetic responses on the hemodynamic consequences of rapid changes in posture in humans. J. Appl. Physiol. 108(3), 523-532 (2010).
30. Stewart JM. Transient orthostatic hypotension is common in adolescents. J. Pediatr. 140(4), 418-424 (2002).
31. Wieling W, Krediet CT, van Dijk N, Linzer M, Tschakovsky ME. Initial orthostatic hypotension: review of a forgotten condition. Clin. Sci. 112(3), 157-165 (2007).
32. Clarke DA, Medow MS, Taneja I, Ocon AJ, Stewart JM. Initial orthostatic hypotension in the young is attenuated by static handgrip. J. Pediatr. 156(6), 1019-1022, 1022.e1 (2010).
33. Stewart JM, Clarke D. "He's dizzy when he stands up": an introduction to initial orthostatic hypotension. J. Pediatr. 158(3), 499-504 (2011).
34. Bernard C. Sur les effets de la section de la portion cephalique du grand sympathique. C.R.Soc. Biol. Paris. 4168-1170 (1852).
35. Charkoudian N, Rabbitts JA. Sympathetic neural mechanisms in human cardiovascular health and disease. Mayo Clin. Proc. 84(9), 822-830 (2009).
36. Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc. Res. 87(2), 198-210 (2010).
37. Huxley VH, Scallan J. Lymphatic fluid: exchange mechanisms and regulation. J. Physiol. (Lond.) 589(Pt 12), 2935-2943 (2011).
38. Platts SH, Tuxhorn JA, Ribeiro LC, Stenger MB, Lee SM, Meck JV. Compression garments as countermeasures to orthostatic intolerance. Aviat. Space. Environ. Med. 80(5), 437-442 (2009).
39. Goldstein DS, Holmes C, Frank SM et al. Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation 106(18), 2358-2365 (2002).
40. Hill L. The influences of the force of gravity on the circulation of the blood. J. Physiol. (Lond.) 1815-1853 (1951).
41. Donegan JF. The physiology of the veins. J. Physiol. (Lond.) 55(3-4), 226-245 (1921).
42. Victor RG, Mark AL. Interaction of cardiopulmonary and carotid baroreflex control of vascular resistance in humans. J. Clin. Invest. 76(4), 1592-1598 (1985).
43. Fadel PJ, Ogoh S, Keller DM, Raven PB. Recent insights into carotid baroreflex function in humans using the variable pressure neck chamber. Exp. Physiol. 88(6), 671-680 (2003).
44. Chapleau MW, Abboud FM. Contrasting effects of static and pulsatile pressure on carotid baroreceptor activity in dogs. Circ. Res. 61(5), 648-658 (1987).
45. Sundlöf G, Wallin BG. Human muscle nerve sympathetic activity at rest. Relationship to blood pressure and age. J. Physiol. (Lond.) 274, 621-637 (1978).
46. Cooper VL, Hainsworth R. Carotid baroreceptor reflexes in humans during orthostatic stress. Exp. Physiol. 86(5), 677-681 (2001).
47. Claydon VE, Hainsworth R. Increased postural sway in control subjects with poor orthostatic tolerance. J. Am. Coll. Cardiol. 46(7), 1309-1313 (2005).
48. Kenny RA, Ingram A, Bayliss J, Sutton R. Head-up tilt: a useful test for investigating unexplained syncope. Lancet 1(8494), 1352-1355 (1986).
49. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol. Rev. 70(4), 963-985 (1990).
50. Dinenno FA, Joyner MJ. Combined NO and PG inhibition augments α-adrenergic vasoconstriction in contracting human skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 287(6), H2576-H2584 (2004).
51. Bayles R, Kn H, Lambert E et al. Epigenetic modification of the norepinephrine transporter gene in postural tachycardia syndrome. Arterioscler. Thromb. Vasc. Biol. 32(8), 1910-1916 (2012).
52. Lambert E, Eikelis N, Esler M et al. Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ. Arrhythm. Electrophysiol. 1(2), 103-109 (2008).
53. Esler M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J. Appl. Physiol. 108(2), 227-237 (2010).
54. Freeman R, Wieling W, Axelrod FB et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 21(2), 69-72 (2011).
55. Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol. Ther. 134(3), 279-286 (2012).
56. Hilz MJ, Ehmann EC, Pauli E et al. Combined counter-maneuvers accelerate recovery from orthostatic hypotension in familial dysautonomia. Acta Neurol. Scand. 126(3), 162-170 (2012).
57. Robertson D, Haile V, Perry SE, Robertson RM, Phillips JA 3rd, Biaggioni I. Dopamine β-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension 18(1), 1-8 (1991).
58. Klein CM, Vernino S, Lennon VA et al. The spectrum of autoimmune autonomic neuropathies. Ann. Neurol. 53(6), 752-758 (2003).
59. Singh NK, Jaiswal AK, Misra S, Srivastava PK. Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications. Acta Neurol. Scand. 75(2), 101-105 (1987).
60. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol. Dis. 46(3), 572-580 (2012).
61. Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-β-hydroxylase deficiency. Lancet 2(8569), 1172-1175 (1987).
62. Mathias CJ. l-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin. Auton. Res. 18(Suppl.) 125-129 (2008).
63. Biaggioni I, Robertson D, Krantz S, Jones M, Haile V. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann. Intern. Med. 121(3), 181-186 (1994).
64. Okamoto LE, Shibao C, Gamboa A et al. Synergistic effect of norepinephrine transporter blockade and a-2 antagonism on blood pressure in autonomic failure. Hypertension 59(3), 650-656 (2012).
65. Jordan J, Shannon JR, Grogan E, Biaggioni I, Robertson D. A potent pressor response elicited by drinking water. Lancet 353(9154), 723 (1999).
66. Mathias CJ, Young TM. Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. Eur. J. Neurol. 11(9), 613-619 (2004).
67. McHugh J, Keller NR, Appalsamy M et al. Portal osmopressor mechanism linked to transient receptor potential vanilloid 4 and blood pressure control. Hypertension 55(6), 1438-1443 (2010).
68. Furlan R, Jacob G, Snell M et al. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation 98(20), 2154-2159 (1998).
69. Singer W, Sletten DM, Opfer-Gehrking TL, Brands CK, Fischer PR, Low PA. Postural tachycardia in children and adolescents: what is abnormal? J. Pediatr. 160(2), 222-226 (2012).
70. Jacob G, Costa F, Shannon JR et al. The neuropathic postural tachycardia syndrome. N. Engl. J. Med. 343(14), 1008-1014 (2000).
71. Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects. Circulation 105(19), 2274-2281 (2002).
72. Stewart JM, Medow MS, Glover JL, Montgomery LD. Persistent splanchnic hyperemia during upright tilt in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 290(2), H665-H673 (2006).
73. Stewart JM, Munoz J, Weldon A. Clinical and physiological effects of an acute α-1 adrenergic agonist and a β-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation 106(23), 2946-2954 (2002).
74. Stewart JM, Medow MS, Cherniack NS, Natelson BH. Postural hypocapnic hyperventilation is associated with enhanced peripheral vasoconstriction in postural tachycardia syndrome with normal supine blood flow. Am. J. Physiol. Heart Circ. Physiol. 291(2), H904-H913 (2006).
75. Stewart JM, Rivera E, Clarke DA et al. Ventilatory baroreflex sensitivity in humans is not modulated by chemoreflex activation. Am. J. Physiol. Heart Circ. Physiol. 300(4), H1492-H1500 (2011).
76. Chen L, Wang L, Sun J et al. Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ. J. 75(4), 927-931 (2011).
77. Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 111(21), 2734-2740 (2005).
78. Bonyhay I, Freeman R. Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation 110(20), 3193-3198 (2004).
79. Shannon JR, Flattem NL, Jordan J et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N. Engl. J. Med. 342(8), 541-549 (2000).
80. Zanzinger J, Czachurski J, Seller H. Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide in vivo. Circ. Res. 75(6), 1073-1077 (1994).
81. Storgaard T, Nedergaard OA. Prejunctional modulation by angiotensins of noradrenaline release from sympathetic neurons in isolated rabbit aorta. Naunyn Schmiedebergs Arch. Pharmacol. 356(6), 706-711 (1997).
82. Kolo LL, Westfall TC, Macarthur H. Nitric oxide decreases the biological activity of norepinephrine resulting in altered vascular tone in the rat mesenteric arterial bed. Am. J. Physiol. Heart Circ. Physiol. 286(1), H296-H303 (2004).
83. Hatanaka Y, Hobara N, Honghua J et al. Neuronal nitric-oxide synthase inhibition facilitates adrenergic neurotransmission in rat mesenteric resistance arteries. J. Pharmacol. Exp. Ther. 316(2), 490-497 (2006).
84. Macarthur H, Mattammal MB, Westfall TC. A new perspective on the inhibitory role of nitric oxide in sympathetic neurotransmission. Biochem. Biophys. Res. Commun. 216(2), 686-692 (1995).
85. Hu ZW, Shi XY, Okazaki M, Hoffman BB. Angiotensin II induces transcription and expression of α 1-adrenergic receptors in vascular smooth muscle cells. Am. J. Physiol. 268(3 Pt 2), H1006-H1014 (1995).
86. Head GA. Role of AT1 receptors in the central control of sympathetic vasomotor function. Clin. Exp. Pharmacol. Physiol. 23(Suppl. 3), S93-S98 (1996).
87. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am. J. Physiol. Heart Circ. Physiol. 287(2), H695-H703 (2004).
88. Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler. Thromb. Vasc. Biol. 20(6), 1430-1442 (2000).
89. Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111(8), 1201-1209 (2003).
90. Raj SR, Biaggioni I, Yamhure PC et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 111(13), 1574-1582 (2005).
91. Medow MS, Bamji N, Clarke D, Ocon AJ, Stewart JM. Reactive oxygen species (ROS) from NADPH and xanthine oxidase modulate the cutaneous local heating response in healthy humans. J. Appl. Physiol. 111(1), 20-26 (2011).
92. Stewart JM, Glover JL, Medow MS. Increased plasma angiotensin II in postural tachycardia syndrome (POTS) is related to reduced blood flow and blood volume. Clin. Sci. 110(2), 255-263 (2006).
93. Stewart JM, Ocon AJ, Clarke D, Taneja I, Medow MS. Defects in cutaneous angiotensin-converting enzyme 2 and angiotensin-(1-7) production in postural tachycardia syndrome. Hypertension 53(5), 767-774 (2009).
94. Raj SR, Black BK, Biaggioni I et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 120(9), 725-734 (2009).
95. Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension 58(2), 167-175 (2011).
96. Gowers WR. A lecture on vagal and vasovagal attacks. Lancet 173, 716-724 (1907).
97. Lewis T. A lecture on vasovagal syncope and the carotid sinus mechanism. Br. Med. J. 1(3723), 873-876 (1932).
98. Ganzeboom KS, Colman N, Reitsma JB, Shen WK, Wieling W. Prevalence and triggers of syncope in medical students. Am. J. Cardiol. 91(8), 1006-1008, A8 (2003).
99. Soteriades ES, Evans JC, Larson MG et al. Incidence and prognosis of syncope. N. Engl. J. Med. 347(12), 878-885 (2002).
100. Aviado DM, Guevara Aviado D. The Bezold-Jarisch reflex. A historical perspective of cardiopulmonary reflexes. Ann. NY Acad. Sci. 940, 48-58 (2001).
101. Hainsworth R. Syncope: what is the trigger? Heart 89(2), 123-124 (2003).
102. Oberg B, Thorén P. Increased activity in left ventricular receptors during hemorrhage or occlusion of caval veins in the cat. A possible cause of the vaso-vagal reaction. Acta Physiol. Scand. 85(2), 164-173 (1972).
103. Scherrer U, Vissing S, Morgan BJ, Hanson P, Victor RG. Vasovagal syncope after infusion of a vasodilator in a hearttransplant recipient. N. Engl. J. Med. 322(9), 602-604 (1990).
104. Liu JE, Hahn RT, Stein KM et al. Left ventricular geometry and function preceding neurally mediated syncope. Circulation 101(7), 777-783 (2000).
105. Mosqueda-Garcia R, Furlan R, Tank J, Fernandez-Violante R. The elusive pathophysiology of neurally mediated syncope. Circulation 102(23), 2898-2906 (2000).
106. Barcroft H, Mcmichael JE, Sharpey- Schafer EP. Posthaemorrhagic fainting. Study by cardiac outputand forearm flow. Lancet 1, 489-491 (1944).
107. Julien C. The enigma of Mayer waves: facts and models. Cardiovasc. Res. 70(1), 12-21 (2006).
108. Hammer PE, Saul JP. Resonance in a mathematical model of baroreflex control: arterial blood pressure waves accompanying postural stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288(6), R1637-R1648 (2005).
109. Verheyden B, Liu J, van Dijk N et al. Steep fall in cardiac output is main determinant of hypotension during drug-free and nitroglycerine-induced orthostatic vasovagal syncope. Heart Rhythm 5(12), 1695-1701 (2008).
110. Cooke WH, Rickards CA, Ryan KL, Kuusela TA, Convertino VA. Muscle sympathetic nerve activity during intense lower body negative pressure to presyncope in humans. J. Physiol. (Lond.) 587(Pt 20), 4987-4999 (2009).
111. Taneja I, Medow MS, Glover JL, Raghunath NK, Stewart JM. Increased vasoconstriction predisposes to hyperpnea and postural faint. Am. J. Physiol. Heart Circ. Physiol. 295(1), H372-H381 (2008).
112. Lagi A, Cencetti S, Corsoni V, Georgiadis D, Bacalli S. Cerebral vasoconstriction in vasovagal syncope: any link with symptoms? A transcranial Doppler study. Circulation 104(22), 2694-2698 (2001).
113. Vaddadi G, Guo L, Esler M et al. Recurrent postural vasovagal syncope: sympathetic nervous system phenotypes. Circ. Arrhythm. Electrophysiol. 4(5), 711-718 (2011).
114. Stewart JM, McLeod KJ, Sanyal S, Herzberg G, Montgomery LD. Relation of postural vasovagal syncope to splanchnic hypervolemia in adolescents. Circulation 110(17), 2575-2581 (2004).
115. Dan D, Hoag JB, Ellenbogen KA, Wood MA, Eckberg DL, Gilligan DM. Cerebral blood flow velocity declines before arterial pressure in patients with orthostatic vasovagal presyncope. J. Am. Coll. Cardiol. 39(6), 1039-1045 (2002).
116. Ocon AJ, Medow MS, Taneja I, Stewart JM. Respiration drives phase synchronization between blood pressure and RR interval following loss of cardiovagal baroreflex during vasovagal syncope. Am. J. Physiol. Heart Circ. Physiol. 300(2), H527-H540 (2011).
117. Jardine DL, Melton IC, Crozier IG et al. Decrease in cardiac output and muscle sympathetic activity during vasovagal syncope. Am. J. Physiol. Heart Circ. Physiol. 282(5), H1804-H1809 (2002).
118. Vaddadi G, Esler MD, Dawood T, Lambert E. Persistence of muscle sympathetic nerve activity during vasovagal syncope. Eur. Heart J. 31(16), 2027-2033 (2010).
119. Looga R. Reflex cardiovascular responses to lung inflation: a review. Respir. Physiol. 109(2), 95-106 (1997).
120. Claydon VE, Hainsworth R. Salt supplementation improves orthostatic cerebral and peripheral vascular control in patients with syncope. Hypertension 43(4), 809-813 (2004).
121. Sheldon RS, Amuah JE, Connolly SJ et al.; Prevention of Syncope Trial. Effect of metoprolol on quality of life in the Prevention of Syncope Trial. J. Cardiovasc. Electrophysiol. 20(10), 1083-1088 (2009).
122. Qingyou Z, Junbao D, Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J. Pediatr. 149(6), 777-780 (2006).
123. Romme JJ, van Dijk N, Go-Schön IK, Reitsma JB, Wieling W. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). Europace 13(11), 1639-1647 (2011).
124. Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 33(5), 1227-1230 (1999).
125. Brignole M, Menozzi C, Moya A et al.; International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial. Circulation 125(21), 2566-2571 (2012).